Skip to main content

Table 1 The clinical characteristics and postoperative rebleeding rate of patients classified by pathological diagnosis of CAA

From: Association of antithrombotic therapy with postoperative rebleeding in patients with cerebral amyloid angiopathy

 

Total cohort (N = 79)

CAA (n = 50)

Non-CAA (n = 29)

P value

Character

 Age, median (range), year

76(55–89)

78(57–89)

73(55–84)

0.001

 Female, No. (%)

41(52)

34 (68)

7 (24)

 < 0.001

 Hypertension, No. (%)

40(51)

21 (42)

19 (66)

0.062

 Diabetes, No. (%)

7(9)

2 (4)

6 (21)

0.025

 Dementia, No. (%)

17(22)

15 (30)

2 (7)

0.022

 Antithrombotic therapy, No. (%)

30(38)

16 (32)

14 (48)

0.229

 Antiplatelets, No. (%)

23(29)

11(22)

12(41)

0.078

 Anticoagulants, No. (%)

11(14)

5(10)

6(21)

0.162

 Combination, No. (%)

4(5)

0

4(14)

0.016

Postoperative rebleeding, No. (%)

14(18)

12(24)

2(7)

0.070

Hematoma vol. (before)*1, Mean (SD), mL

82(33)

82(33)

83(33)

0.866

Hematoma vol. (after)*2, Mean (SD), mL

5.9(5.6)

6.2(5.8)

5.2(5.5)

0.430

  1. CAA Cerebral amyloid angiopathy
  2. *1: Preoperative hematoma volume
  3. *2: Residual hematoma volume immediately after surgery